The Indian market for GLP-1 agonist weight-loss drugs reached a Moving Annual Total (MAT) of ₹2,215 crore as of July 2026.
Pharmaceutical firms are rapidly expanding their portfolios to capitalize on the growing demand for obesity treatments across the country.
Experts emphasize that while the market is booming, maintaining quality standards in drug manufacturing is essential for long-term patient safety.